真实世界中仑伐替尼治疗放射性碘难治性分化型甲状腺癌的生存预测因素
多中心回顾性队列研究纳入3家意大利甲状腺癌转诊中心的55例放射性碘难治性分化型甲状腺癌(RR-DTC)患者,分析仑伐替尼治疗前及治疗后的生存预测因素;治疗前ECOG体能状态与放射性碘亲和性独立预测无进展生存,治疗后最佳影像学缓解独立预测无进展生存与总生存。
要点
- 治疗前ECOG评分0-1分且放射性碘亲和者客观缓解率100%,中位无进展生存45个月。
- 治疗后最佳影像学缓解是唯一独立生存预测因素(无进展生存P=.001,总生存P=.013)。
- 仑伐替尼在96.4%患者中为一线激酶抑制剂,中位随访48个月。
核心结论
- 体能状态良好且放射性碘亲和性疾病的RR-DTC患者从仑伐替尼获得最大临床获益。
- 治疗开始后,客观缓解是唯一独立的生存预测因素。
研究设计与样本
- 多中心、回顾性队列研究,纳入3家意大利甲状腺癌转诊中心的55例接受仑伐替尼治疗的RR-DTC患者。
- 主要结局指标为无进展生存(PFS)和总生存(OS)。
主要发现
- 仑伐替尼在96.4%的受试者中为一线激酶抑制剂,中位随访48个月。
- 中位PFS为26个月(95%CI 19.06-32.93),中位OS为70个月(95%CI 36-111.99)。
- 治疗前ECOG体能状态与PFS独立相关(P<.001;HR 18.82;95%CI 3.65-97.08;以评分0-1为参照),与OS独立相关(P=.001;HR 6.20;95%CI 2.11-18.20;以评分0-1为参照)。
- 放射性碘亲和性与PFS独立相关(P=.047;HR 3.74;95%CI 1.01-13.76;以亲和性疾病为参照)。
- ECOG状态良好(0-1)且放射性碘亲和的患者客观缓解率为100%,中位PFS为45个月,中位随访81个月期间无死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). The definition of predictive factors of survival is incomplete. OBJECTIVE: To identify pre- and posttreatment survival predictors in a real-life cohort of RR-DTC treated with lenvatinib. DESIGN: Multicenter, retrospective, cohort study. SETTING: 3 Italian thyroid cancer referral centers. PARTICIPANTS: 55 RR-DTC treated with lenvatinib. MAIN OUTCOME MEASURES: Progression-free survival (PFS) and overall survival (OS). RESULTS: Lenvatinib was the first-line kinase-inhibitor in 96.4% of subjects. Median follow-up was 48 months. Median PFS and OS were 26 [95% confidence interval (CI) 19.06-32.93] and 70 months (95% CI 36-111.99), respectively. Pretreatment setting: Eastern Cooperative Oncology Group (ECOG) performance status was independently related to PFS [P < .001; hazard ratio (HR) 18.82; 95% CI 3.65-97.08: score 0-1 as reference] and OS (P = .001; HR 6.20; 95% CI 2.11-18.20; score 0-1 as reference); radioactive iodine (RAI) avidity was independently related to PFS (P = .047; HR 3.74; 95% CI 1.01-13.76; avid disease as reference). Patients with good ECOG status (0-1) and RAI-avid disease obtained objective response in 100% of cases and achieved a median PFS of 45 months without any death upon a median follow-up of 81 months. Posttreatment setting: the best radiological response independently predicted PFS (P = .001; HR 4.6; 95% CI 1.89-11.18; partial/complete response as reference) and OS (P = .013; HR 2.94; 95% CI 1.25-6.89; partial/complete response as reference). CONCLUSION: RR-DTC with good performance status and RAI-avid disease obtains the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.
引用
- Marotta V, Rocco D, Crocco A, et al. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life. J Clin Endocrinol Metab. 2024. PMID: 38501238. doi:10.1210/clinem/dgae181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。